Innoviva Net Profit Margin 2010-2023 | INVA

Innoviva net profit margin from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
Innoviva Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-12-31 $0.31B $0.18B 58.06%
2023-09-30 $0.29B $0.05B 17.24%
2023-06-30 $0.29B $0.23B 80.69%
2023-03-31 $0.32B $0.23B 73.82%
2022-12-31 $0.33B $0.22B 64.95%
2022-09-30 $0.37B $0.29B 78.55%
2022-06-30 $0.40B $0.10B 24.50%
2022-03-31 $0.40B $0.19B 47.10%
2021-12-31 $0.39B $0.27B 67.43%
2021-09-30 $0.38B $0.31B 82.40%
2021-06-30 $0.37B $0.27B 72.40%
2021-03-31 $0.34B $0.25B 73.55%
2020-12-31 $0.34B $0.22B 66.47%
2020-09-30 $0.32B $0.22B 66.87%
2020-06-30 $0.30B $0.23B 76.00%
2020-03-31 $0.29B $0.19B 66.32%
2019-12-31 $0.26B $0.16B 60.54%
2019-09-30 $0.27B $0.38B 141.89%
2019-06-30 $0.26B $0.38B 146.74%
2019-03-31 $0.26B $0.40B 151.52%
2018-12-31 $0.26B $0.40B 151.72%
2018-09-30 $0.25B $0.19B 75.70%
2018-06-30 $0.24B $0.17B 70.17%
2018-03-31 $0.23B $0.15B 63.91%
2017-12-31 $0.22B $0.13B 61.47%
2017-09-30 $0.19B $0.10B 52.60%
2017-06-30 $0.18B $0.09B 52.27%
2017-03-31 $0.15B $0.07B 48.32%
2016-12-31 $0.13B $0.06B 44.36%
2016-09-30 $0.11B $0.04B 33.93%
2016-06-30 $0.09B $0.02B 19.35%
2016-03-31 $0.07B $-0.01B -6.94%
2015-12-31 $0.06B $-0.02B -36.36%
2015-09-30 $0.04B $-0.04B -102.56%
2015-06-30 $0.03B $-0.06B -215.38%
2015-03-31 $0.02B $-0.11B -700.00%
2014-12-31 $0.01B $-0.17B -2112.50%
2014-09-30 $0.00B $-0.20B -10150.00%
2014-06-30 $0.00B $-0.23B -22900.00%
2014-03-31 $0.00B $-0.20B -20100.00%
2013-12-31 $0.00B $-0.17B -5666.67%
2013-09-30 $0.01B $-0.15B -1887.50%
2013-06-30 $0.01B $-0.14B -1544.44%
2013-03-31 $0.01B $-0.14B -1555.56%
2012-12-31 $0.14B $-0.02B -13.33%
2012-09-30 $0.13B $-0.02B -17.91%
2012-06-30 $0.14B $-0.02B -14.39%
2012-03-31 $0.14B $-0.01B -5.56%
2011-12-31 $0.02B $-0.12B -504.35%
2011-09-30 $0.03B $-0.10B -392.00%
2011-06-30 $0.02B $-0.09B -366.67%
2011-03-31 $0.02B $-0.08B -350.00%
2010-12-31 $0.02B $-0.08B -350.00%
2010-09-30 $0.02B $-0.09B -414.29%
2010-06-30 $0.02B $-0.09B -400.00%
2010-03-31 $0.02B $-0.09B -423.81%
2009-12-31 $0.03B $-0.09B -340.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.998B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62